The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis

IF 1.8 4区 医学 Q3 DERMATOLOGY
Wenzhuo Jiang, Qiujv Li, Wenjun Zheng
{"title":"The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis","authors":"Wenzhuo Jiang,&nbsp;Qiujv Li,&nbsp;Wenjun Zheng","doi":"10.1007/s00403-025-04174-2","DOIUrl":null,"url":null,"abstract":"<div><p>This study aims to compare the efficacy of IL-17 and IL-23 biologics in the treatment of plaque psoriasis (Psoriasis vulgaris) in patients with metabolic syndrome (MetS) and to explore the effects of different biologics on metabolic indicators, particularly regarding the differences in efficacy during long-term treatment. This is a randomized controlled clinical trial involving 120 moderates to severe plaque psoriasis patients, of which 60 have metabolic syndrome and 60 do not. The patients were randomly assigned to three groups: IL-17 biologics group, IL-23 biologics group, and cyclosporine control group. Treatment lasted for three months, with evaluation indicators including psoriatic lesion assessment (PASI score), blood glucose levels, lipid profile (triglycerides, HDL-C), inflammatory markers (CRP, ESR, IL-6), etc. Patients were assessed at baseline, after one month, and after three months of treatment for both clinical efficacy and changes in metabolic indicators. Both IL-17 and IL-23 biologics demonstrated superior efficacy compared to cyclosporine in treating plaque psoriasis. After one month and three months of treatment, PASI scores in the IL-17 and IL-23 groups were significantly lower than in the control group, and the therapeutic effects were more pronounced (<i>P</i> &lt; 0.05). The IL-17 and IL-23 groups also showed better improvements in blood glucose, blood lipids (TG and HDL-C), and inflammatory markers (CRP, ESR, IL-6) compared to the control group. After three months of treatment, fasting blood glucose, fasting insulin, triglycerides, and CRP levels were significantly lower in the IL-17 and IL-23 groups than in the control group (<i>P</i> &lt; 0.05). Metabolic syndrome had some impact on treatment outcomes, with the efficacy of IL-17 and IL-23 biologics being lower in patients with metabolic abnormalities compared to those without metabolic syndrome. However, the IL-23 biologic showed less impact from metabolic syndrome. IL-17 biologics had a rapid effect in the short term, while IL-23 biologics demonstrated superior efficacy in long-term treatment, particularly at the three-month mark, where both efficacy and metabolic improvements were better than the IL-17 group. Both IL-17 and IL-23 biologics are more effective than cyclosporine in treating plaque psoriasis and can improve metabolic indicators in patients. Although metabolic syndrome impacts the efficacy of IL-17 biologics, IL-23 biologics are less affected by metabolic syndrome and demonstrate better long-term efficacy. Therefore, IL-23 biologics are recommended for long-term treatment in plaque psoriasis patients with metabolic syndrome.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Dermatological Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00403-025-04174-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study aims to compare the efficacy of IL-17 and IL-23 biologics in the treatment of plaque psoriasis (Psoriasis vulgaris) in patients with metabolic syndrome (MetS) and to explore the effects of different biologics on metabolic indicators, particularly regarding the differences in efficacy during long-term treatment. This is a randomized controlled clinical trial involving 120 moderates to severe plaque psoriasis patients, of which 60 have metabolic syndrome and 60 do not. The patients were randomly assigned to three groups: IL-17 biologics group, IL-23 biologics group, and cyclosporine control group. Treatment lasted for three months, with evaluation indicators including psoriatic lesion assessment (PASI score), blood glucose levels, lipid profile (triglycerides, HDL-C), inflammatory markers (CRP, ESR, IL-6), etc. Patients were assessed at baseline, after one month, and after three months of treatment for both clinical efficacy and changes in metabolic indicators. Both IL-17 and IL-23 biologics demonstrated superior efficacy compared to cyclosporine in treating plaque psoriasis. After one month and three months of treatment, PASI scores in the IL-17 and IL-23 groups were significantly lower than in the control group, and the therapeutic effects were more pronounced (P < 0.05). The IL-17 and IL-23 groups also showed better improvements in blood glucose, blood lipids (TG and HDL-C), and inflammatory markers (CRP, ESR, IL-6) compared to the control group. After three months of treatment, fasting blood glucose, fasting insulin, triglycerides, and CRP levels were significantly lower in the IL-17 and IL-23 groups than in the control group (P < 0.05). Metabolic syndrome had some impact on treatment outcomes, with the efficacy of IL-17 and IL-23 biologics being lower in patients with metabolic abnormalities compared to those without metabolic syndrome. However, the IL-23 biologic showed less impact from metabolic syndrome. IL-17 biologics had a rapid effect in the short term, while IL-23 biologics demonstrated superior efficacy in long-term treatment, particularly at the three-month mark, where both efficacy and metabolic improvements were better than the IL-17 group. Both IL-17 and IL-23 biologics are more effective than cyclosporine in treating plaque psoriasis and can improve metabolic indicators in patients. Although metabolic syndrome impacts the efficacy of IL-17 biologics, IL-23 biologics are less affected by metabolic syndrome and demonstrate better long-term efficacy. Therefore, IL-23 biologics are recommended for long-term treatment in plaque psoriasis patients with metabolic syndrome.

靶向IL-17和IL-23途径的生物制剂对斑块型银屑病代谢指标的影响
本研究旨在比较IL-17和IL-23生物制剂治疗代谢综合征(MetS)斑块型银屑病(psoriasis vulgaris)的疗效,探讨不同生物制剂对代谢指标的影响,特别是长期治疗期间疗效的差异。这是一项随机对照临床试验,涉及120例中度至重度斑块性银屑病患者,其中60例有代谢综合征,60例无代谢综合征。患者随机分为三组:IL-17生物制剂组、IL-23生物制剂组和环孢素对照组。治疗3个月,评估指标包括银屑病病变评估(PASI评分)、血糖水平、血脂(甘油三酯、HDL-C)、炎症标志物(CRP、ESR、IL-6)等。在基线、治疗1个月后和治疗3个月后评估患者的临床疗效和代谢指标的变化。与环孢素相比,IL-17和IL-23生物制剂在治疗斑块型银屑病方面均表现出优越的疗效。治疗1个月和3个月后,IL-17组和IL-23组PASI评分均显著低于对照组,且治疗效果更明显(P < 0.05)。与对照组相比,IL-17和IL-23组在血糖、血脂(TG和HDL-C)和炎症标志物(CRP、ESR、IL-6)方面也有更好的改善。治疗3个月后,IL-17组、IL-23组空腹血糖、空腹胰岛素、甘油三酯、CRP水平均显著低于对照组(P < 0.05)。代谢综合征对治疗结果有一定影响,与无代谢综合征的患者相比,代谢异常患者使用IL-17和IL-23生物制剂的疗效较低。而IL-23生物学指标受代谢综合征的影响较小。IL-17生物制剂在短期内具有快速疗效,而IL-23生物制剂在长期治疗中表现出优越的疗效,特别是在三个月时,其疗效和代谢改善均优于IL-17组。IL-17和IL-23生物制剂治疗斑块型银屑病均比环孢素更有效,并能改善患者的代谢指标。虽然代谢综合征会影响IL-17生物制剂的疗效,但IL-23生物制剂受代谢综合征的影响较小,长期疗效更好。因此,IL-23生物制剂被推荐用于伴随代谢综合征的斑块型银屑病患者的长期治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
3.30%
发文量
30
审稿时长
4-8 weeks
期刊介绍: Archives of Dermatological Research is a highly rated international journal that publishes original contributions in the field of experimental dermatology, including papers on biochemistry, morphology and immunology of the skin. The journal is among the few not related to dermatological associations or belonging to respective societies which guarantees complete independence. This English-language journal also offers a platform for review articles in areas of interest for dermatologists and for publication of innovative clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信